Technology and Innovation

Driving innovation in Cutting-edge Technology

As forward-thinking solution providers, we excel at transforming ideas into reality, promoting innovation through the development and investment in cutting-edge technology.

Our approach

Impact

Recognizing the potential of investing in cutting-edge technology to enhance efficiency, spur innovation, save costs, and elevate the quality of life across sectors, we allocate resources to foster long-term economic growth and development in this domain.

Proactive Innovation

As proactive problem solvers adept at guiding projects from conception to completion, we drive innovation through the development and investment in cutting-edge technology.

Substancial Investment

Our investment in groundbreaking technology originates from the utilization of software and/or AI in various sectors such as agriculture, real estate, construction, retail, sales and marketing, legal, risk and compliance, media, telecom, security, transportation, automotive, education, data, and analytics, among others.

Dedicated to investing in, developing, and owning companies across multiple regions, sectors and business models.

We support promising companies and products by offering adaptable capital and clinical expertise to propel innovation and enhance outcomes for patients.

Life Science

Investing in products that target unmet Medical needs

In collaboration with pharmaceutical, biotech, and medical technology firms, we finance products that target unmet medical needs, aiming to enhance the quality of life for patients globally.

Our approach

Support

We support promising companies and products by offering adaptable capital and clinical expertise to propel innovation and enhance outcomes for patients.

Expertise

FirstStein Capital invests by offering operational expertise through our global medical network, providing access to investment capital, resources, and even medical infrastructure.

Impact of Investment

We aim to generate value for investors through investments in promising late-stage innovative life sciences, intending to maximize positive impact with minimal clinical risk.

Insights

Insights

All referenced data unless otherwise noted is as of September 30, 2023.

Past performance is not a guide to future results. The products, services, information and/or materials contained within these web pages may not be available for residents of certain jurisdictions.

Copyright© FirstStein Capital GmbH 2023. All rights reserved. Information on this site is proprietary and may not to be reproduced, transferred, or distributed in any form without prior written permission from FirstStein. It is delivered on an “as is” basis without warranty or liability.